T Twenty-eight patients from a single surgeon and center underwent atrial fibrillation surgery using a diode-pumped laser. A left-sided modified (pulmonary vein encircling with connecting lesions) or a complete modified Cox-Maze III operation was employed. Of the 28 patients, 23 were available for retrospective evaluation and Holter monitoring, and 21 patients elected to participate in a follow-up study. The Society for Thoracic Surgeons database was used for in-hospital experience. All 21 patients were studied >6 months after surgery and received a 24-hour Holter monitor and an SF-36v2 quality of life survey. The mean follow-up time was 18.1 months. Among this group, one patient was in atrial fibrillation and four experienced atrial tachyarrhythmias at the time of Holter monitoring. Five patients (24%) underwent cardioversion after operation, and nine patients (43%) were on warfarin. No patients were treated with repeat ablation. One patient required a pacemaker postoperatively. We observed 95% freedom from atrial fibrillation and 76% freedom from all atrial tachyarrhythmias in the study group. No complications or deaths were device related. In conclusion, the use of a diode-pumped laser appears to be safe and effective for the treatment of atrial fibrillation.
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here is interest in curing atrial fi brillation (AF) because it is responsible for signifi cant morbidity and mortality in the general population. AF aff ects 2.2 million people in the USA alone, with an incidence that increases with age (1). AF is directly related to increased mortality, increased risk of stroke, and exacerbation of heart failure (2-4).
In 1993, the Cox-Maze surgery demonstrated promising results with particular emphasis on freedom from stroke (5) . Th e operation was considered by many to be technically diffi cult, and some had diffi culty replicating Dr. Cox's success with similar atrial lesions. A number of energy sources have been developed to approximate and simplify the creation of Cox's original Maze lesion set. Th e 810-nm laser is used in this series of patients to create lesion lines on the atrium.
A laser employing 810-nm wavelength light was developed originally to block ventricular tachyarrhythmias (6) . Th e eff ectiveness of this device in animal studies suggested that it may be useful in AF surgery as well (7) . Animal studies on the atrium showed a satisfactory safety profi le for the laser technology (7) . Th is study reports on the use of a diode-pumped laser system to treat AF in 28 patients.
MATERIALS AND METHODS
From January 2005 through October 2007, we operated on 28 patients with symptomatic AF-classifi ed as paroxysmal AF (n = 11, 39%), persistent AF (n = 15, 54%), or long-standing persistent AF (n = 2, 7%)-using a left-sided or full modifi ed Cox-Maze procedure with the 810-nm AtriLaze™ Surgical Ablation System (EndoPhotoniX, Inc; Eagan, MN).
Th e laser consists of a plastic molded handpiece that houses the eff erent end of a fi ber-optic cable that is directed approximately 60 degrees off axis. Th e tip consists of a small plastic nipple with distal concavity that allows the instillation of saline at the point of laser exit from the device, while being superfi cial to the epicardium. Th is layer of saline allows uniform conduction of laser energy into the endocardium and transmurally to the epicardial portion of the atrium (8) .
Th e operations were performed in a single center by one surgeon. Institutional review board approval was obtained for retrospective review of data and additional monitoring. After informed consent was obtained, patients were contacted 6 months or longer after operation and were evaluated with a 
Surgical technique
All lesions were created on cold (32°C) arrested hearts. Cold sanguinous hyperkalemic cardioplegia was used with an initial arresting dose of 20 mEq/L potassium and 1.0 g/L magnesium.
In left-sided Maze lesions created for patients with paroxysmal AF, the left atrium was incised anterior to the right and left pulmonary veins in a semicircular fashion, with the incision starting on the dome of the left atrium and being complete in the posterior wall of the atrium ( Figure 1 ). All left-sided Maze lesions included a pulmonary vein-encircling lesion created along the base of the atrium parallel to the posterior leafl et of the mitral valve and then anterior to the left superior and inferior pulmonary vein, connecting the middle of the dome of the atrium to complete a circle (box lesion). Th ese lesion sets then had extension lines into the left atrial appendage and extension lines to the posterior leafl et of the mitral valve. Great care was taken to preserve the posterior leafl et of the mitral valve.
In patients with persistent and long-standing persistent AF, right-sided lesions were created to complete the modifi ed Cox-Maze III. Two incisions were made in the right atrium ( Figure 2) . A diagonal incision along the right atrial appendage was created and extended medially through the trabeculated portion. Th is oblique incision was then connected to the tricuspid valve annulus. A second incision was made perpendicular to the axis of the superior and inferior vena cava line. Th is lesion line was extended to the tricuspid valve annulus. A T-shaped lesion was created by forming a lesion from the lateral aspect of the inferior vena cava to the lateral aspect of the superior vena cava. In all cases, the wand was held adjacent to the endocardium of the atria with the laser beam pointed outward toward the epicardium of the heart. Th e wand was moved manually and stepwise over the tissue at an approximate progressive rate of 3.4 cm per minute, in a painting fashion.
Incisions were closed with monofi lament 4-0 polypropylene sutures.
Postoperative protocol
All patients were treated with amiodarone immediately postoperatively through discharge. Amiodarone was given intravenously for 24 hours at 0.5 mg/ min and then orally at 400 mg three times daily. All patients were discharged on warfarin, with a target international normalized ratio of 2.5 to 3.0. Upon discharge, antiarrhythmic therapy with low-dose amiodarone at 200 mg daily was continued based on the judgment of the investigators and consultant cardiologists.
During postoperative visits, standard 12-lead electrocardiograms were observed. Six months or more after surgery, followup 24-hour Holter monitoring was conducted. Th e patients also completed an SF-36v2 quality of life survey at that time. Rhythm failure was defi ned as an atrial tachyarrhythmia for ≥30 seconds. Data on adverse events and their relatedness to the device were collected and reviewed by the clinical investigators. Data were entered into a standardized Society of Th oracic Surgeons database and examined through descriptive analysis.
RESULTS
Among the 28 patients who underwent AF surgery, 25 had New York Heart Association Class III or Class IV heart failure before the operation; 7 had a prior cardiac surgical procedure through a sternotomy; and 25 had been treated with antiarrhythmic medications before the operation (Table 1 ). In addition, 27 patients required a concomitant cardiac surgery procedure (Table 1) . One patient underwent sole-therapy AF Surgical treatment of atrial fibrillation with diode-pumped laser ablation with a right and left modifi ed Cox-Maze III. Catheter ablation was not a good option for that patient due to his left atrial appendage thrombus. Twenty-one patients consented to the follow-up retrospective study, and their individual data appear in Table 2 . Mean follow-up duration was 18.1 months (range, 6.2-37.4 months). Two patients denied consent for Holter monitoring, and fi ve patients died-two within 30 days, one within a year, and two within 2.5 years of the procedure. No complications or deaths were device related.
Holter analysis demonstrated that 20 of the 21 patients (95%) were free from AF. Four patients (19%) had atrial fl utter. Th us, 16 of the 21 patients (76%) were free from all atrial tachyarrhythmias. Five patients (24%) underwent cardioversion >90 days after the operation. At the time of study follow-up, no patient required repeat ablation. One study patient (5%) received a pacemaker postoperatively; another patient required an implantable defi brillator postoperatively for wide-complex ventricular tachycardia.
At the time of follow-up, 43% of patients were on warfarin anticoagulation, 38% of patients were on an antiarrhythmic (amiodarone or sotalol), 52% were on beta-blockers, 14% were on calcium channel blockers, and 10% were on digoxin AF indicates atrial fibrillation; ATA, atrial tachyarrhythmias; BMI, body mass index; CAB, coronary artery bypass graft; DCCV, direct current cardioversion; EF, ejection fraction; LOS, length of stay; NYHA, New York Heart Association heart failure clinical classification.
( Table 3 ). Also, 38% of patients were on angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers.
On the follow-up SF-36v2 quality of life survey, 71% graded their general health as excellent, very good, or good, and 67% of respondents reported that their general health was better than before surgery. Additionally, 91% of respondents indicated that they had only minor limitation or no limitation at all with walking several hundred yards postoperatively, whereas 38% of respondents responded that they were "limited a lot" in walking several hundred yards prior to surgery.
DISCUSSION
Th is analysis of the use of AtriLaze for the purpose of creating modifi ed Cox-Maze lesion lines in conjunction with openheart surgery is limited in that it is a retrospective analysis of concomitant surgeries. Th e analysis is also limited by the comorbidities of patients who undergo AF therapy in conjunction with other cardiac surgical procedures. Some of these results can be attributed to the effi cacy of the surgery for valvular and coronary artery disease. Th e atrial rhythm analysis, however, is not only accurate and precise but is refl ective of the effi cacy of the device.
All but one of the study patients were free of AF >6 months after operation. More than three fourths of patients were free from all atrial tachyarrhythmias at follow-up. Th e predominant atrial tachyarrhythmia was atrial fl utter, and none of these patients have required postoperative catheter-based "touch-up" ablation. Even though over half of the patients were on beta-blockers, about one third were on antiarrhythmics and less than half were still anticoagulated.
Stand-alone AF surgery is uncommon, even to this day. Many patients with valvular disease also have AF. Consequently, most of the patients' primary indication is their valve pathology, with AF as a secondary diagnosis.
We conclude that the use of the diode-pumped laser for the surgical treatment of AF appears to be safe and eff ective in creating modifi ed Cox-Maze lesion lines at the time of open-heart surgery for the purpose of reducing or eliminating AF or other atrial tachyarrhythmias in an at-risk patient population. 
